Cargando…

Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()

BACKGROUND: Vulvar pseudotumoral herpes infections have been reported in HIV-positive patients. A 32-year-old HIV-negative woman presented with a 6-month history of a vulvar pseudotumor that had been unresponsive to oral acyclovir and valacyclovir, as well as topical imiquimod. OBJECTIVE: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jun, Krauss, John C., Moyal-Barracco, Micheline, Washer, Laraine L., Haefner, Hope K., Parker-Featherstone, Ebony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714585/
https://www.ncbi.nlm.nih.gov/pubmed/35028373
http://dx.doi.org/10.1016/j.ijwd.2021.06.002
_version_ 1784623937964998656
author Hu, Jun
Krauss, John C.
Moyal-Barracco, Micheline
Washer, Laraine L.
Haefner, Hope K.
Parker-Featherstone, Ebony
author_facet Hu, Jun
Krauss, John C.
Moyal-Barracco, Micheline
Washer, Laraine L.
Haefner, Hope K.
Parker-Featherstone, Ebony
author_sort Hu, Jun
collection PubMed
description BACKGROUND: Vulvar pseudotumoral herpes infections have been reported in HIV-positive patients. A 32-year-old HIV-negative woman presented with a 6-month history of a vulvar pseudotumor that had been unresponsive to oral acyclovir and valacyclovir, as well as topical imiquimod. OBJECTIVE: This study aimed to evaluate the therapeutic efficacy of a multidrug regimen for vulvar pseudotumor herpes infection in an HIV-negative patient. METHODS: Histology revealed multinucleated giant cells, consistent with a herpes infection. The patient's herpes simplex virus type 2 was resistant to acyclovir. Immunomodulatory agents (thalidomide and topical imiquimod) were started. RESULTS: The lesion enlarged after 6 weeks of treatment. Topical cidofovir 1% gel was added. There was gradual decrease in the pseudotumor size. After 7 months, the Pseudotumor had resolved. CONCLUSION: This is the first reported case of vulvar pseudotumoral herpes in an immunocompetent, HIV-negative patient. Oral thalidomide, in association with topical imiquimod and topical cidofovir, was effective in treating acyclovir-resistant pseudotumoral herpes of the vulva.
format Online
Article
Text
id pubmed-8714585
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87145852022-01-12 Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()() Hu, Jun Krauss, John C. Moyal-Barracco, Micheline Washer, Laraine L. Haefner, Hope K. Parker-Featherstone, Ebony Int J Womens Dermatol Original Research BACKGROUND: Vulvar pseudotumoral herpes infections have been reported in HIV-positive patients. A 32-year-old HIV-negative woman presented with a 6-month history of a vulvar pseudotumor that had been unresponsive to oral acyclovir and valacyclovir, as well as topical imiquimod. OBJECTIVE: This study aimed to evaluate the therapeutic efficacy of a multidrug regimen for vulvar pseudotumor herpes infection in an HIV-negative patient. METHODS: Histology revealed multinucleated giant cells, consistent with a herpes infection. The patient's herpes simplex virus type 2 was resistant to acyclovir. Immunomodulatory agents (thalidomide and topical imiquimod) were started. RESULTS: The lesion enlarged after 6 weeks of treatment. Topical cidofovir 1% gel was added. There was gradual decrease in the pseudotumor size. After 7 months, the Pseudotumor had resolved. CONCLUSION: This is the first reported case of vulvar pseudotumoral herpes in an immunocompetent, HIV-negative patient. Oral thalidomide, in association with topical imiquimod and topical cidofovir, was effective in treating acyclovir-resistant pseudotumoral herpes of the vulva. Elsevier 2021-06-20 /pmc/articles/PMC8714585/ /pubmed/35028373 http://dx.doi.org/10.1016/j.ijwd.2021.06.002 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Hu, Jun
Krauss, John C.
Moyal-Barracco, Micheline
Washer, Laraine L.
Haefner, Hope K.
Parker-Featherstone, Ebony
Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title_full Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title_fullStr Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title_full_unstemmed Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title_short Vulvar pseudotumoral acyclovir-resistant herpes in an HIV-negative, non-immunosuppressed patient: A therapeutic challenge()()()
title_sort vulvar pseudotumoral acyclovir-resistant herpes in an hiv-negative, non-immunosuppressed patient: a therapeutic challenge()()()
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714585/
https://www.ncbi.nlm.nih.gov/pubmed/35028373
http://dx.doi.org/10.1016/j.ijwd.2021.06.002
work_keys_str_mv AT hujun vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge
AT kraussjohnc vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge
AT moyalbarraccomicheline vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge
AT washerlarainel vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge
AT haefnerhopek vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge
AT parkerfeatherstoneebony vulvarpseudotumoralacyclovirresistantherpesinanhivnegativenonimmunosuppressedpatientatherapeuticchallenge